Source:http://linkedlifedata.com/resource/pubmed/id/16500924
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-4-10
|
pubmed:abstractText |
Intrathecal (IT) substance P-Saporin (SP-SAP), a 33-kDa-targeted neurotoxin, produces selective destruction of superficial neurokinin 1 receptor (NK1r)-bearing cells in the spinal dorsal horn. In rats, SP-SAP prevents the formation of hyperalgesia and can reverse established neuropathic pain behavior in rodents. To determine the safety of this therapeutic modality in a large animal model, beagles received bolus IT lumbar injections of vehicle, SP-SAP (1.5, 15, 45, or 150 microg), or a nontargeted preparation of saporin (SAP, 150 microg) for immunohistological analysis of spinal cords. Doses of 15 microg SP-SAP and above produced a significant and equivalent loss of NK1r-bearing cells and dendrites in lumbar laminae II and I compared to vehicle- or SAP-treated animals. Cervical regions in all animals displayed no loss of NK1r immunoreactivity as compared to controls. Total numbers of neurons in the lumbar dorsal horn or alpha-motor neurons in the ventral horn demonstrated no significant changes. No increases in the astrocytic marker glial fibrillary acidic protein were noted following treatment with SP-SAP, suggesting a lack of generalized neurotoxicity. Additional dogs received doses of 1.5-150 microg SP-SAP or SAP and were sacrificed after 28 or 90 days to assess behavioral and physiological parameters. Although some acute motor signs were observed with both SP-SAP and SAP, no long-lasting significant events were noted in any of these animals. These data indicate no adverse toxicity at doses up to 10 times those necessary for producing loss of superficial NK1r-bearing neurons in a large animal model.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1096-6080
|
pubmed:author |
pubmed-author:AllenJeffrey WJW,
pubmed-author:CizkovaDasaD,
pubmed-author:GhilardiJoseph RJR,
pubmed-author:GrafeMarjorie RMR,
pubmed-author:HoraisKjerstiK,
pubmed-author:LappiDouglas ADA,
pubmed-author:MantyhPatrick WPW,
pubmed-author:RichterPhillipP,
pubmed-author:RogersScott DSD,
pubmed-author:TozierNicoleN,
pubmed-author:YakshTony LTL
|
pubmed:issnType |
Print
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
286-98
|
pubmed:dateRevised |
2010-9-17
|
pubmed:meshHeading |
pubmed-meshheading:16500924-Animals,
pubmed-meshheading:16500924-Behavior, Animal,
pubmed-meshheading:16500924-Dogs,
pubmed-meshheading:16500924-Injections, Spinal,
pubmed-meshheading:16500924-Neurotoxins,
pubmed-meshheading:16500924-Ribosome Inactivating Proteins, Type 1,
pubmed-meshheading:16500924-Spinal Cord,
pubmed-meshheading:16500924-Substance P
|
pubmed:year |
2006
|
pubmed:articleTitle |
Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs.
|
pubmed:affiliation |
Department of Anesthesiology, University of California, San Diego, La Jolla, California 92093-0818, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|